Stockscreener 앱 받기
125.84
1.31%
-1.67
전일 마감가:
$127.51
열려 있는:
$127.1
하루 거래량:
3.06M
Relative Volume:
0.43
시가총액:
$156.13B
수익:
$29.05B
순이익/손실:
$8.11B
주가수익비율:
19.49
EPS:
6.4563
순현금흐름:
$9.16B
1주 성능:
-0.63%
1개월 성능:
+6.75%
6개월 성능:
+16.05%
1년 성능:
+36.18%
1일 변동 폭
$124.90
$127.80
1주일 범위
$124.49
$128.25
52주 변동 폭
$88.57
$128.70
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.84 | 158.20B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,075.47 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.92 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.70 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.40 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.83 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - Insider Monkey
Skandinaviska Enskilda Banken AB publ Acquires 252,108 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Quadrant Capital Group LLC Has $3.82 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative? - Yahoo Finance UK
Is Gilead Sciences a Bargain After 40% Share Price Surge and Pipeline Updates? - Yahoo Finance
Some CAR-Ts Are Thriving While Others Are Falling Behind. Why? - Citeline News & Insights
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Johnson Financial Group Inc. Buys 4,239 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Korea Investment CORP Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Kiltearn Partners LLP Sells 11,600 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Steward Partners Investment Advisory LLC Sells 2,152 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILEAD FOUNDATION COMMITS OVER $3 MILLION TO ADDRESS FOOD INSECURITY AS COMMUNITIES FACE RISING HEALTH RISKS - Gaye Magazine
Gilead Plans 800K-SF Expansion at Foster City Campus - Hoodline
U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035 - GlobeNewswire Inc.
Te Ahumairangi Investment Management Ltd Purchases 9,624 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - The Business Journals
Northwest & Ethical Investments L.P. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences Inc. stock oversold or undervaluedMarket Growth Report & AI Forecasted Entry and Exit Points - moha.gov.vn
Global Retirement Partners LLC Acquires Shares of 20,074 Gilead Sciences, Inc. $GILD - MarketBeat
Vera Therapeutics appoints former Gilead executive to board By Investing.com - Investing.com South Africa
Dir Kramer Files To Sell 5,611 Of Gilead Sciences Inc [GILD] - TradingView
Vera Therapeutics appoints former Gilead executive to board - Investing.com
Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact - Citeline News & Insights
Verity & Verity LLC Sells 43,792 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Oak Associates Ltd. OH Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jefferies Financial Group Inc. Has $7.06 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Escalator: Gilead Sciences, Medtronic, Labcorp and more - Medical Marketing and Media
CreativeOne Wealth LLC Has $3.52 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead acquires Sprint’s pre-clinical TREX1 cancer programme - PharmiWeb.com
Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m - Pharmaceutical Technology
Truist Financial Initiates Coverage on Gilead Sciences (NASDAQ:GILD) - MarketBeat
Gilead scoops up a preclinical cancer program - BioPharma Dive
Bob Allen joins Gilead’s public affairs team - Medical Marketing and Media
Gilead Sciences stock rating reiterated at Outperform by BMO Capital - Investing.com
Is Gilead Sciences Stock Outperforming the Dow? - Barchart.com
Summit Global Investments Buys 10,233 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Edgar Lomax Co. VA Sells 3,735 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: About To Break Out (NASDAQ:GILD) - Seeking Alpha
Gilead acquires Sprint Bioscience TREX1 programme - European Biotechnology Magazine
Advisors Asset Management Inc. Has $22.84 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report - biocentury.com
Power Check: Apple, Rockwell Automation and Gilead Sciences - CNBC
GILD: Truist Securities Lowers Price Target for Gilead Sciences - GuruFocus
From the Lab to Runway: HIV Unwrapped Helps Transform Stigma by Giving Lab Coats a Makeover - Gilead Sciences
Sprint Bioscience sells cancer program TREX1 to Gilead - Biostock
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo Finance
BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead - TradingView
Prudential Financial Inc. Buys 486,379 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Merck's oral HIV treatment as effective as Gilead's Biktarv - The Jerusalem Post
Gilead Foundation Commits Over $3 Million to Address Food Insecurity - Yahoo Finance
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.12%
0.30%
자본화:
|
볼륨(24시간):